Nimotuzumab with chemo and radiation for advanced pancreatic cancer
Part of Cancer, Digestive system clinical trials.
This trial tests adding nimotuzumab (a targeted antibody) to standard chemoradiation for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with pancreatic cancer (confirmed by biopsy or cytology).
- Your cancer is locally advanced or has spread to only a few spots (3 or fewer metastases).
- Your doctor says the cancer cannot be removed by surgery, or you choose not to have surgery.
- You are physically active and able to care for yourself (ECOG score 0 or 1).
- You have not had radiation to your upper abdomen before, and you have not received any chemotherapy or other systemic anti-cancer treatment.
- You have at least one tumor that can be measured on scans (according to RECIST 1.1).
- Your organ and bone marrow function are adequate (blood tests will confirm).
- You are not pregnant or breastfeeding, and you agree to use effective birth control if applicable.
- You have no history of other cancers (except cured skin or cervical cancer), no HIV or syphilis infection, and no active hepatitis B or C.
- You have not had major surgery in the last 30 days, and you have not used EGFR-targeted drugs in the last 30 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a targeted drug (nimotuzumab) to standard chemotherapy after surgery can help prevent pancreatic cancer from coming back. It is designed for people who have had their pancreatic cancer completely or nearly completely removed.
This trial tests adding the targeted drug nimotuzumab to standard chemotherapy and radiation for people with esophageal cancer that cannot be removed by surgery. It may help shrink the tumor or stop it from growing further.
This trial tests a drug called nimotuzumab combined with standard chemotherapy and radiation for patients with esophageal cancer. It may help improve treatment effectiveness for those whose cancer has not spread to other parts of the body.
This trial tests a drug called nimotuzumab combined with radiation therapy for older adults (65+) with advanced head and neck cancer. It aims to help control the cancer when chemotherapy is not an option.
This trial tests adding nimotuzumab (a targeted therapy) to standard chemotherapy for people whose pancreatic cancer was completely removed with surgery. The goal is to see if this combination helps prevent the cancer from coming back.
This trial tests a combination of two treatments: a targeted antibody therapy called nimotuzumab with chemotherapy, followed by a procedure that uses electrical pulses to destroy tumor cells. It is for people with locally advanced pancreatic cancer that has not spread, and aims to see if this approach can help control the disease.
Hear when a new Pancreatic Cancer Non-resectable trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.